Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

NCT01625338 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

534

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: SOF
DRUG: RBV
DRUG: Peg-IFN

Sponsor

Gilead Sciences